A detailed history of Polar Capital Holdings PLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Polar Capital Holdings PLC holds 2,536,058 shares of XENE stock, worth $99.8 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
2,536,058
Previous 2,612,108 2.91%
Holding current value
$99.8 Million
Previous $112 Million 12.07%
% of portfolio
0.6%
Previous 0.7%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$36.25 - $43.75 $2.76 Million - $3.33 Million
-76,050 Reduced 2.91%
2,536,058 $98.9 Million
Q1 2024

May 15, 2024

SELL
$42.66 - $50.04 $19.4 Million - $22.7 Million
-454,520 Reduced 14.82%
2,612,108 $112 Million
Q4 2023

Feb 14, 2024

BUY
$28.7 - $46.46 $1.8 Million - $2.92 Million
62,881 Added 2.09%
3,066,628 $141 Million
Q3 2023

Nov 14, 2023

SELL
$34.16 - $39.73 $625,947 - $728,012
-18,324 Reduced 0.61%
3,003,747 $103 Million
Q2 2023

Dec 13, 2023

BUY
$34.84 - $43.54 $183,014 - $228,715
5,253 Added 0.17%
3,022,071 $116 Million
Q2 2023

Aug 14, 2023

BUY
$34.84 - $43.54 $105 Million - $132 Million
3,022,071 New
3,022,071 $116 Million
Q1 2023

Dec 13, 2023

BUY
$33.46 - $40.35 $437,355 - $527,414
13,071 Added 0.44%
3,016,818 $108 Million
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $12.7 Million - $15.1 Million
383,152 Added 14.39%
3,045,874 $120 Million
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $3.78 Million - $4.88 Million
122,663 Added 4.83%
2,662,722 $96.1 Million
Q2 2022

Aug 15, 2022

BUY
$25.44 - $35.16 $8.9 Million - $12.3 Million
350,000 Added 15.98%
2,540,059 $77.3 Million
Q1 2022

May 16, 2022

BUY
$25.09 - $33.13 $12.6 Million - $16.6 Million
502,015 Added 29.74%
2,190,059 $67 Million
Q4 2021

Feb 14, 2022

BUY
$15.6 - $35.4 $26.3 Million - $59.8 Million
1,688,044 New
1,688,044 $52.7 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.45B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.